An FDA approval for Otezla in scalp psoriasis could bring Celgene closer to meeting analysts' expectations for peak product sales of $2 billion. But the company will have to come up with a good strategy for dealing with a raft of challenges, from payer pushback to competition from biosimilar versions of older drugs.
